Latest Lassa Stories
Recent Lassa fever outbreaks in Africa show vital need for new products that can be processed in any clinical or field lab DENVER and NEW ORLEANS, May 7 /PRNewswire-FirstCall/ -- Corgenix Medical Corporation (OTC Bulletin Board: CONX), a worldwide developer and marketer of diagnostic test kits, has announced an extension of the collaborative effort for developing test kits for the detection of viral hemorrhagic fever (VHF).
Siga Technologies, a company specializing in the development of pharmaceutical agents to fight bio-warfare pathogens, has received the third year of grant funding for its ongoing Lassa fever antiviral research.
WASHINGTON (Reuters) - A genetically engineered virus may offer the first effective vaccine against Lassa fever, a sometimes deadly hemorrhagic fever common in West Africa, U.S. and Canadian scientists said on Monday.
Lassa fever, first described in 1969 in Lassa, is an acute viral hemorrhagic fever. Clinical cases were known a decade before this but were not associated with this viral pathogen. It is endemic in West African countries and causes approximately 5,000 deaths. The Natal Multimammate Mouse is the primary animal host. The rodent is a source of protein but the virus is usually transmitted by the contact with the feces and urine of animals accessing grain stores in residences. The lassa virus...
- Growing in low tufty patches.